CN101711237B - 氮杂肽衍生物 - Google Patents
氮杂肽衍生物 Download PDFInfo
- Publication number
- CN101711237B CN101711237B CN2008800216013A CN200880021601A CN101711237B CN 101711237 B CN101711237 B CN 101711237B CN 2008800216013 A CN2008800216013 A CN 2008800216013A CN 200880021601 A CN200880021601 A CN 200880021601A CN 101711237 B CN101711237 B CN 101711237B
- Authority
- CN
- China
- Prior art keywords
- compound
- pharmaceutically acceptable
- compounds
- atazanavir
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *C(c(cc1)ccc1-c1ccccn1)N(C[C@@]([C@](Cc1ccccc1)NC([C@](C(*)(*)*)NC(O*)=O)=O)O)NC([C@](*)NC(O*)=O)=O Chemical compound *C(c(cc1)ccc1-c1ccccn1)N(C[C@@]([C@](Cc1ccccc1)NC([C@](C(*)(*)*)NC(O*)=O)=O)O)NC([C@](*)NC(O*)=O)=O 0.000 description 11
- RJFFVAGYPXHKIN-UHFFFAOYSA-N CC(CN1CCN(C)CC1)=O Chemical compound CC(CN1CCN(C)CC1)=O RJFFVAGYPXHKIN-UHFFFAOYSA-N 0.000 description 1
- LWAQMFOMLLTHKZ-UHFFFAOYSA-N CC(CN1CCNCC1)=O Chemical compound CC(CN1CCNCC1)=O LWAQMFOMLLTHKZ-UHFFFAOYSA-N 0.000 description 1
- LOBSVGRXQAHJDT-UHFFFAOYSA-N CC(CN1CCOCC1)=O Chemical compound CC(CN1CCOCC1)=O LOBSVGRXQAHJDT-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/58—Pyridine rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93420107P | 2007-06-12 | 2007-06-12 | |
| US60/934,201 | 2007-06-12 | ||
| US6762708P | 2008-02-29 | 2008-02-29 | |
| US61/067,627 | 2008-02-29 | ||
| PCT/US2008/007331 WO2008156632A1 (en) | 2007-06-12 | 2008-06-12 | Azapeptide derivatives |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011102869075A Division CN102424668A (zh) | 2007-06-12 | 2008-06-12 | 氮杂肽衍生物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101711237A CN101711237A (zh) | 2010-05-19 |
| CN101711237B true CN101711237B (zh) | 2013-08-07 |
Family
ID=39730784
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008800216013A Expired - Fee Related CN101711237B (zh) | 2007-06-12 | 2008-06-12 | 氮杂肽衍生物 |
| CN2011102869075A Pending CN102424668A (zh) | 2007-06-12 | 2008-06-12 | 氮杂肽衍生物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011102869075A Pending CN102424668A (zh) | 2007-06-12 | 2008-06-12 | 氮杂肽衍生物 |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US20090036357A1 (en:Method) |
| EP (3) | EP2003120B9 (en:Method) |
| JP (1) | JP2010529196A (en:Method) |
| KR (2) | KR20120029480A (en:Method) |
| CN (2) | CN101711237B (en:Method) |
| AR (1) | AR066972A1 (en:Method) |
| AT (2) | ATE447554T1 (en:Method) |
| AU (1) | AU2008267048C1 (en:Method) |
| BR (2) | BRPI0823520A2 (en:Method) |
| CA (1) | CA2692028C (en:Method) |
| CO (1) | CO6241121A2 (en:Method) |
| CY (1) | CY1109766T1 (en:Method) |
| DE (1) | DE602008000255D1 (en:Method) |
| DK (1) | DK2003120T3 (en:Method) |
| ES (3) | ES2394952T3 (en:Method) |
| HR (1) | HRP20100065T1 (en:Method) |
| MX (1) | MX2009013565A (en:Method) |
| PL (1) | PL2003120T3 (en:Method) |
| PT (1) | PT2003120E (en:Method) |
| RS (1) | RS51226B (en:Method) |
| RU (2) | RU2448958C2 (en:Method) |
| SI (1) | SI2003120T1 (en:Method) |
| TW (1) | TW200908970A (en:Method) |
| WO (1) | WO2008156632A1 (en:Method) |
| ZA (1) | ZA200909079B (en:Method) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080241289A1 (en) * | 2007-02-23 | 2008-10-02 | Auspex Pharmaceuticals, Inc. | Preparation and utility of non-nucleoside reverse transcriptase inhibitors |
| ES2394952T3 (es) | 2007-06-12 | 2013-02-07 | Concert Pharmaceuticals Inc. | Derivados de axapéptido como inhibidores de la proteasa VIH |
| WO2010041241A2 (en) * | 2008-10-06 | 2010-04-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Hiv-1 integrase derived peptides and compositions |
| WO2010132663A1 (en) * | 2009-05-13 | 2010-11-18 | Concert Pharmaceticals, Inc. | Pegylated azapeptide derivatives as hiv protease inhibitors |
| WO2010135424A1 (en) * | 2009-05-19 | 2010-11-25 | Glaxosmithkline Llc | Chemical compounds |
| CA2784530C (en) * | 2009-12-21 | 2018-05-22 | Janssen R&D Ireland | Degradable removable implant for the sustained release of an active compound |
| WO2011080562A1 (en) | 2009-12-29 | 2011-07-07 | Hetero Research Foundation | Novel aza-peptides containing 2,2-disubstituted cyclobutyl and/or substituted alkoxy benzyl derivatives as antivirals |
| PL3135656T3 (pl) | 2011-06-20 | 2019-07-31 | H. Lundbeck A/S | Deuterowane 1-piperazyno-3-fenyloindany do leczenia schizofrenii |
| CN106543073A (zh) * | 2015-09-17 | 2017-03-29 | 宁波杰尔盛化工有限公司 | 2-[4-（2-吡啶基）苄基]-肼羧酸叔丁酯的制备方法 |
| AU2016361612B2 (en) * | 2015-12-02 | 2021-07-29 | Merck Sharp & Dohme Llc | Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine |
| LT3436461T (lt) | 2016-03-28 | 2024-03-12 | Incyte Corporation | Pirolotriazino junginiai kaip tam inhibitoriai |
| JOP20180009A1 (ar) | 2017-02-06 | 2019-01-30 | Gilead Sciences Inc | مركبات مثبط فيروس hiv |
| WO2019025250A1 (en) | 2017-08-04 | 2019-02-07 | Basf Se | SUBSTITUTED TRIFLUOROMETHYLOXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI |
| CN111386273B (zh) | 2017-09-27 | 2024-06-14 | 因赛特公司 | 可用作tam抑制剂的吡咯并三嗪衍生物的盐 |
| CN113164398B (zh) * | 2018-06-29 | 2023-11-03 | 因赛特公司 | Axl/mer抑制剂的制剂 |
| TWI829205B (zh) | 2018-07-30 | 2024-01-11 | 美商基利科學股份有限公司 | 抗hiv化合物 |
| WO2021178779A1 (en) | 2020-03-06 | 2021-09-10 | Incyte Corporation | Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors |
| AU2021257341A1 (en) * | 2020-04-16 | 2022-11-17 | The Medical College Of Wisconsin, Inc. | Aerosolized formulations of HIV protease inhibitors for the treatment of airway reflux |
| CN114426568B (zh) * | 2022-01-11 | 2023-04-25 | 嘉兴安谛康生物科技有限公司 | 2-氧代-3-吡咯烷基丙腈类化合物及其药物组合物和用途 |
| CN121464144A (zh) | 2023-05-31 | 2026-02-03 | 吉利德科学公司 | 抗hiv化合物 |
| CN116987024B (zh) * | 2023-08-01 | 2026-02-13 | 浙江荣耀生物科技股份有限公司 | 一种阿扎那韦中间体的制备方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006014282A2 (en) * | 2004-07-06 | 2006-02-09 | Abbott Laboratories | Prodrugs of hiv protease inhibitors |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI87783C (fi) | 1985-05-15 | 1993-02-25 | Wellcome Found | Foerfarande foer framstaellning av terapeutiskt anvaendbara 2',3'-dideoxinukleosider |
| GB8815265D0 (en) | 1988-06-27 | 1988-08-03 | Wellcome Found | Therapeutic nucleosides |
| US5539122A (en) * | 1989-05-23 | 1996-07-23 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| GB9009861D0 (en) | 1990-05-02 | 1990-06-27 | Glaxo Group Ltd | Chemical compounds |
| EP0674513B1 (en) | 1992-12-29 | 1996-09-25 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
| ES2293638T3 (es) | 1994-03-25 | 2008-03-16 | Isotechnika, Inc. | Mejora de la eficacia de farmacos por deuteracion. |
| US6221335B1 (en) * | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| TW409125B (en) * | 1996-04-22 | 2000-10-21 | Novartis Ag | Antivirally active heterocyclic azahexane derivatives |
| US5849911A (en) | 1996-04-22 | 1998-12-15 | Novartis Finance Corporation | Antivirally active heterocyclic azahexane derivatives |
| WO1997046514A1 (en) | 1996-05-31 | 1997-12-11 | Novartis Ag | Process for the preparation of hydrazine derivatives useful as intermediates for the preparation of peptide analogues |
| US6087383A (en) * | 1998-01-20 | 2000-07-11 | Bristol-Myers Squibb Company | Bisulfate salt of HIV protease inhibitor |
| US6440710B1 (en) * | 1998-12-10 | 2002-08-27 | The Scripps Research Institute | Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds |
| GB9914821D0 (en) | 1999-06-24 | 1999-08-25 | Glaxo Group Ltd | Compounds |
| GB9925962D0 (en) | 1999-11-02 | 1999-12-29 | Novartis Ag | Organic compounds |
| ATE234299T1 (de) * | 1999-12-03 | 2003-03-15 | Pfizer Prod Inc | Sulfamoylheteroarylpyrazolverbindungen zur verwendung als analgetisches/entzündungshemmendes mittel |
| CA2444116C (en) | 2001-05-03 | 2009-01-20 | F. Hoffmann-La Roche Ag | Pharmaceutical dosage form of amorphous nelfinavir mesylate |
| JP2005503425A (ja) | 2001-05-24 | 2005-02-03 | アレックザ モレキュラー デリヴァリー コーポレイション | 所定の吸入ルートによる薬剤エステルの送出 |
| IL159849A0 (en) | 2001-08-31 | 2004-06-20 | Bristol Myers Squibb Co | Use of atazanavir in hiv therapy |
| TW200413273A (en) * | 2002-11-15 | 2004-08-01 | Wako Pure Chem Ind Ltd | Heavy hydrogenation method of heterocyclic rings |
| US7553844B2 (en) | 2003-02-21 | 2009-06-30 | Jarrow Formulas, Inc. | Methods for treatment of HIV or malaria using combinations of chloroquine and protease inhibitors |
| US20050131017A1 (en) | 2003-12-11 | 2005-06-16 | Degoey David A. | HIV protease inhibiting compounds |
| US20050148523A1 (en) | 2003-12-15 | 2005-07-07 | Colonno Richard J. | Method of treating HIV infection in atazanavir-resistant patients using a combination of atazanavir and another protease inhibitor |
| US7829720B2 (en) * | 2004-05-04 | 2010-11-09 | Bristol-Myers Squibb Company | Process for preparing atazanavir bisulfate and novel forms |
| KR20070083839A (ko) | 2004-09-29 | 2007-08-24 | 코디스 코포레이션 | 안정한 무정형 라파마이신 유사 화합물의 약학적 투약 형태 |
| JP2008521934A (ja) | 2004-12-03 | 2008-06-26 | メルク エンド カムパニー インコーポレーテッド | Ｕｇｔ１ａ１によって代謝される薬物の薬物動態を改善するためのアタザナビルの使用 |
| CA2624179A1 (en) * | 2005-10-06 | 2007-04-12 | Auspex Pharmaceuticals, Inc. | Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties |
| US7750168B2 (en) * | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
| JO2630B1 (en) | 2006-04-13 | 2012-06-17 | نوفارتيس ايه جي | Organic compounds |
| JP2010502702A (ja) * | 2006-09-05 | 2010-01-28 | シェーリング コーポレイション | 脂質管理およびアテローム性動脈硬化症および脂肪肝の治療治療において使用される医薬組成物 |
| ES2394952T3 (es) | 2007-06-12 | 2013-02-07 | Concert Pharmaceuticals Inc. | Derivados de axapéptido como inhibidores de la proteasa VIH |
| US20090076097A1 (en) * | 2007-09-14 | 2009-03-19 | Protia, Llc | Deuterium-enriched atazanavir |
| WO2010132663A1 (en) | 2009-05-13 | 2010-11-18 | Concert Pharmaceticals, Inc. | Pegylated azapeptide derivatives as hiv protease inhibitors |
-
2008
- 2008-06-12 ES ES11155667T patent/ES2394952T3/es active Active
- 2008-06-12 EP EP08252023A patent/EP2003120B9/en active Active
- 2008-06-12 BR BRPI0823520-1A patent/BRPI0823520A2/pt not_active IP Right Cessation
- 2008-06-12 TW TW097122018A patent/TW200908970A/zh unknown
- 2008-06-12 DK DK08252023.0T patent/DK2003120T3/da active
- 2008-06-12 BR BRPI0813911-3A patent/BRPI0813911A2/pt not_active IP Right Cessation
- 2008-06-12 CN CN2008800216013A patent/CN101711237B/zh not_active Expired - Fee Related
- 2008-06-12 CN CN2011102869075A patent/CN102424668A/zh active Pending
- 2008-06-12 KR KR1020127003399A patent/KR20120029480A/ko not_active Withdrawn
- 2008-06-12 RS RSP-2010/0034A patent/RS51226B/sr unknown
- 2008-06-12 CA CA2692028A patent/CA2692028C/en not_active Expired - Fee Related
- 2008-06-12 JP JP2010512186A patent/JP2010529196A/ja active Pending
- 2008-06-12 AT AT08252023T patent/ATE447554T1/de active
- 2008-06-12 KR KR1020107000675A patent/KR101185899B1/ko not_active Expired - Fee Related
- 2008-06-12 WO PCT/US2008/007331 patent/WO2008156632A1/en not_active Ceased
- 2008-06-12 ES ES09075359T patent/ES2395137T3/es active Active
- 2008-06-12 US US12/157,712 patent/US20090036357A1/en not_active Abandoned
- 2008-06-12 MX MX2009013565A patent/MX2009013565A/es active IP Right Grant
- 2008-06-12 AU AU2008267048A patent/AU2008267048C1/en not_active Ceased
- 2008-06-12 AR ARP080102501A patent/AR066972A1/es unknown
- 2008-06-12 EP EP09075359A patent/EP2116532B1/en active Active
- 2008-06-12 SI SI200830012T patent/SI2003120T1/sl unknown
- 2008-06-12 RU RU2010100821/04A patent/RU2448958C2/ru not_active IP Right Cessation
- 2008-06-12 AT AT09075359T patent/ATE536343T1/de active
- 2008-06-12 PT PT08252023T patent/PT2003120E/pt unknown
- 2008-06-12 DE DE602008000255T patent/DE602008000255D1/de active Active
- 2008-06-12 EP EP11155667A patent/EP2322509B1/en active Active
- 2008-06-12 ES ES08252023T patent/ES2356334T3/es active Active
- 2008-06-12 PL PL08252023T patent/PL2003120T3/pl unknown
-
2009
- 2009-12-11 CO CO09141805A patent/CO6241121A2/es not_active Application Discontinuation
- 2009-12-18 ZA ZA2009/09079A patent/ZA200909079B/en unknown
-
2010
- 2010-02-03 HR HR20100065T patent/HRP20100065T1/hr unknown
- 2010-02-03 CY CY20101100099T patent/CY1109766T1/el unknown
- 2010-04-06 US US12/755,184 patent/US8158805B2/en not_active Expired - Fee Related
-
2012
- 2012-01-19 RU RU2012101881/04A patent/RU2012101881A/ru not_active Application Discontinuation
- 2012-03-02 US US13/411,089 patent/US8258309B2/en not_active Expired - Fee Related
- 2012-08-27 US US13/595,511 patent/US20130041156A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006014282A2 (en) * | 2004-07-06 | 2006-02-09 | Abbott Laboratories | Prodrugs of hiv protease inhibitors |
Non-Patent Citations (3)
| Title |
|---|
| Cihlar et al.Suppression of HIV-1 protease inhibitor resistance by posphonate-mediated solvent anchoring.《Journal of molecular biology》.2006,第363卷(第3期),635-647. * |
| Xu zhongmin et al.Process research and development for an efficient synthesis of the HIV protease inhibitor BMS-232632.《Organic procesws research & development》.2002,第6卷(第3期),323-328. * |
| Zhang Huiping et al.A facile and efficient syntheis of d3-labelled reyatazTM.《Journal of labelled compounds and radiopharmaceuticals》.2005,第48卷(第14期),1041-1047. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101711237B (zh) | 氮杂肽衍生物 | |
| CN105669751B (zh) | 非环核苷酸磷酰胺类化合物及其盐的制备以及在抗病毒方面的应用 | |
| US9108902B2 (en) | Deuterated 2-amino-3-hydroxypropanoic acid derivatives | |
| WO2009148600A2 (en) | Deuterated lysine-based compounds | |
| HK1154862A (en) | Azapeptide derivatives as hiv protease inhibitors | |
| HK1136576B (en) | Azapeptide derivatives as hiv protease inhibitors | |
| HK1127345B (en) | Azapeptide derivatives as hiv protease inhibitors | |
| AU2012216511A1 (en) | Azapeptide derivatives | |
| EP2163553A1 (en) | Arene connected polyamine macroring derivatives, preparation methods and pharmaceutical uses thereof | |
| WO2021257669A1 (en) | Synthesis of substituted arylmethylureas, analogues, and crystalline forms thereof and methods of using same | |
| KR20210072765A (ko) | N-(4-플루오로-3-(6-(3-메틸피리딘-2-일)-[1,2,4]트리아졸로[1,5-a]피리미딘-2-일)페닐)-2,4-디메틸옥사졸-5-카복사미드의 고체 형태 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130807 Termination date: 20150612 |
|
| EXPY | Termination of patent right or utility model |